Diabetes Meds: 2020 UpdateVersión en línea A skills activity to test your knowledge of GLP-1 Receptor agonists and SGLT-2 Inhibitors. por Krista Tull 1 GLP-1 Receptor Agonist 2 SGLT-2 Inhibitor Recommended to reduce CV risk in patient with Type 2 DM & established ASCVD Decreases appetite Slows gastric emptying Stimulates insulin secretion Suppresses glucagon secretion Trulicity, Byetta, Bydureon, Victoza, Ozempic In patients with Type 2 DM and established HF, this may be considered to reduce risk of HF hospitalization Reduces glucose reabsorption Increases loss of glucose in urine Invokana, Farxiga, Jardiance Avoid in patients with impaired kidney function Use with caution in patients receiving higher dose diuretics
Crear